BridgeBio Pharma (BBIO) Revenue (2019 - 2026)

BridgeBio Pharma (BBIO) has 8 years of Revenue data on file, last reported at $194.5 million in Q1 2026.

• For the quarter ending Q1 2026, Revenue rose 66.78% year-over-year to $194.5 million; the trailing twelve-month figure through Mar 2026 stood at $580.0 million (up 355.17% YoY), and the FY2025 full-year result was $502.1 million, up 126.26% from the prior year.
• Revenue improved to $194.5 million in Q1 2026, from $154.2 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $211.1 million in Q1 2024 to a low of $338000.0 in Q3 2022.
• A 5-year average of $59.1 million and a median of $4.1 million in 2023 frame the typical range for Revenue.
• Across the five-year window, Revenue slumped 97.77% in 2023 and surged 11461.88% in 2024, its largest moves.
• Tracing BBIO's Revenue over 5 years: stood at $1.9 million in 2022, then dropped by 6.68% to $1.7 million in 2023, then soared by 237.08% to $5.9 million in 2024, then soared by 2521.18% to $154.2 million in 2025, then climbed by 26.16% to $194.5 million in 2026.
• Business Quant data shows BBIO's Revenue at $194.5 million in Q1 2026, $154.2 million in Q4 2025, and $120.7 million in Q3 2025.